FY2026 EPS Estimate for PTC Therapeutics Reduced by Analyst

PTC Therapeutics, Inc. (NASDAQ:PTCT) – Stock analysts at Leerink Partnrs dropped their FY2026 EPS estimates for PTC Therapeutics in a note issued to investors on Sunday, November 16th. Leerink Partnrs analyst J. Schwartz now forecasts that the biopharmaceutical company will earn ($2.42) per share for the year, down from their prior estimate of ($1.66). The consensus estimate for PTC Therapeutics’ current full-year earnings is ($4.52) per share.

PTC Therapeutics (NASDAQ:PTCT) last released its earnings results on Tuesday, November 4th. The biopharmaceutical company reported $0.20 earnings per share (EPS) for the quarter, beating the consensus estimate of ($1.19) by $1.39. PTC Therapeutics had a net margin of 35.65% and a negative return on equity of 106.31%. The firm had revenue of $211.01 million during the quarter, compared to analyst estimates of $177.42 million. During the same period last year, the business earned ($1.39) earnings per share. The business’s revenue was up 7.2% on a year-over-year basis. PTC Therapeutics has set its FY 2025 guidance at EPS.

Other equities research analysts have also recently issued reports about the company. Royal Bank Of Canada increased their target price on PTC Therapeutics from $70.00 to $82.00 and gave the stock an “outperform” rating in a research note on Wednesday, November 5th. Citigroup increased their price objective on shares of PTC Therapeutics from $50.00 to $75.00 and gave the company a “neutral” rating in a research report on Wednesday, November 5th. Jefferies Financial Group raised their price objective on shares of PTC Therapeutics from $63.00 to $77.00 and gave the company a “buy” rating in a research note on Tuesday, October 28th. Cantor Fitzgerald reiterated an “overweight” rating and issued a $118.00 target price on shares of PTC Therapeutics in a research note on Wednesday, September 3rd. Finally, Barclays raised their price target on shares of PTC Therapeutics from $46.00 to $68.00 and gave the company an “equal weight” rating in a research report on Wednesday, November 5th. Ten research analysts have rated the stock with a Buy rating, six have issued a Hold rating and one has given a Sell rating to the stock. Based on data from MarketBeat, the company presently has an average rating of “Moderate Buy” and a consensus price target of $75.40.

PTC Therapeutics Stock Up 1.4%

PTCT stock opened at $76.69 on Wednesday. The business has a 50 day moving average of $66.02 and a 200 day moving average of $54.90. The firm has a market cap of $6.16 billion, a PE ratio of 11.00 and a beta of 0.60. PTC Therapeutics has a twelve month low of $35.95 and a twelve month high of $77.46.

Insider Activity at PTC Therapeutics

In other PTC Therapeutics news, Director Emma Reeve sold 7,333 shares of PTC Therapeutics stock in a transaction that occurred on Wednesday, November 12th. The shares were sold at an average price of $74.50, for a total value of $546,308.50. Following the completion of the sale, the director owned 6,666 shares of the company’s stock, valued at approximately $496,617. The trade was a 52.38% decrease in their position. The transaction was disclosed in a document filed with the SEC, which is accessible through this hyperlink. Also, Director Allan Steven Jacobson sold 12,000 shares of the business’s stock in a transaction on Friday, October 3rd. The shares were sold at an average price of $65.00, for a total transaction of $780,000.00. Following the sale, the director owned 17,451 shares of the company’s stock, valued at approximately $1,134,315. This represents a 40.75% decrease in their ownership of the stock. The disclosure for this sale is available in the SEC filing. Over the last three months, insiders have sold 261,995 shares of company stock valued at $16,547,129. Insiders own 5.50% of the company’s stock.

Institutional Trading of PTC Therapeutics

A number of hedge funds have recently bought and sold shares of the company. CANADA LIFE ASSURANCE Co increased its position in PTC Therapeutics by 55.9% during the third quarter. CANADA LIFE ASSURANCE Co now owns 33,984 shares of the biopharmaceutical company’s stock valued at $2,060,000 after acquiring an additional 12,191 shares during the last quarter. Woodline Partners LP bought a new stake in shares of PTC Therapeutics during the 3rd quarter valued at about $6,481,000. Qube Research & Technologies Ltd increased its position in shares of PTC Therapeutics by 27.4% during the 3rd quarter. Qube Research & Technologies Ltd now owns 430,934 shares of the biopharmaceutical company’s stock valued at $26,446,000 after purchasing an additional 92,771 shares during the last quarter. Palo Alto Investors LP lifted its stake in shares of PTC Therapeutics by 112.2% in the 3rd quarter. Palo Alto Investors LP now owns 862,613 shares of the biopharmaceutical company’s stock worth $52,939,000 after purchasing an additional 456,144 shares during the period. Finally, Parkman Healthcare Partners LLC boosted its holdings in shares of PTC Therapeutics by 11.4% in the third quarter. Parkman Healthcare Partners LLC now owns 202,363 shares of the biopharmaceutical company’s stock worth $12,419,000 after buying an additional 20,720 shares during the last quarter.

About PTC Therapeutics

PTC Therapeutics, Inc, a biopharmaceutical company, focuses on the discovery, development, and commercialization of medicines to patients with rare disorders in the United States and internationally. The company offers Translarna and Emflaza for the treatment of Duchenne muscular dystrophy; Upstaza to treat aromatic l-amino acid decarboxylas (AADC) deficiency, a central nervous system disorder; Tegsedi and Waylivra for the treatment of rare diseases; and Evrysdi to treat spinal muscular atrophy (SMA) in adults and children.